目的：探析《中华人民共和国药典》国际协调的思路和方法。方法：通过查阅各国药典、国际人用药品注册技术协调会指导原则、药典讨论组协调案、我国相关部门和世界贸易组织发布的标准协调法规文件，并与《中华人民共和国药典》相关内容进行对比，总结各国药典国际协调现状和未来策略，分析《中华人民共和国药典》国际协调的现实意义和应考虑的问题。结果：《中华人民共和国药典》的国际协调应坚持国家整体利益第一的原则，遵循"三腿凳子"理论；采用和参与制定国际协调的药典标准缺一不可，是否采用国际协调的药典标准应结合我国国情决定，不采用国际协调的药典标准应有正当理由；《中华人民共和国药典》应在国际协调基础上坚持特色并转化为国际标准。结论：建议《中华人民共和国药典》建立健全国际协调的制度规范，充分行使制定国际药品标准的权利，从而提高我国药品标准水平，扩大《中华人民共和国药典》的国际影响。
Objective: Exploring the ideas and methods of international harmonization of the Chinese Pharmacopoeia. Mehtods: By reviewing the Chinese Pharmacopoeia, the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines, the Pharmacopoeia Discussion Group harmonization cases, the standard harmonization regulations issued by the Chinese government department and the World Trade Organization, compared with the relevant contents of Chinese Pharmacopoeia, summarized the current status and future strategies of international harmonization of pharmacopoeia, and analyzed the practical significance of the international harmonization of the Chinese Pharmacopoeia and the issues that should be considered. Results: The international harmonization of the Chinese Pharmacopoeia should adhere to the principle of the country's overall interests first, and follow the theory of ‘three leg stools’; the adoption and participation in the development of internationally harmonized pharmacopoeia standards are indispensable, whether to adopt internationally harmonized pharmacopoeia standards or not should be determined in light of China's national conditions, and there should be justification for not adopting internationally harmonized Pharmacopoeia standards; the Chinese Pharmacopoeia should adhere to the characteristics on the basis of international coordination. Conclusion: It is recommended that the Chinese Pharmacopoeia establish the regulations, fully exercise the right to develop international drug standards, so as to improve the level of China's drug standards, and expanding the Chinese Pharmacopoeia international influence.
[1] World Health Organization. Review of World Pharmacopoeias[EB/OL].(2013-03)[2019-07-04]. https://www.who.int/medicines/areas/quality_safety/quality_assurance/resources/InternationalMeetingWorldPharmacopoeias_QAS13-512Rev1_25032013.pdf?ua=1.
[2] Wiggins J M, Skutnik J A, Shimek-Cox J L, et al. The Ideal Pharmacopeia[J]. Pharmaceutical Technology,2008,32(11):122-125.
[3] 国家质量监督检验检疫总局. 采用国际标准管理办法[E B/O L]. (2001-12-04)[2019-08-20]. http://www.aqsiq.gov.cn/xxgk_13386/jlgg_12538/zjl/20012002/200610/t20061027_239119.htm.
[4] 徐昕怡,许华玉,靳桂民,等. 各国药典理化检验方法通则(附录)概况分析[J]. 中国药学杂志,2018,53(15):1323-1332.
[5] Cathie VIELLE. 10th Edition of the Ph. Eur. Summary of Achievements[S]. 2019.
[6] 日本药品医疗器械综合机构(PMDA). 日本药典的制作方针和药品各条的讨论体制[S]. 2019.
[7] United States Pharmacopoeia. Harmonization Status for General Chapters[EB/OL].[2019-08-13]. https://www.usp.org/harmonized-standards/pdg/general-chapters.
[8] United States Pharmacopoeia. Harmonization Status for General Methods[EB/OL].[2019-08-13]. https://www.usp.org/harmonized-standards/pdg/general-methods.
[9] United States Pharmacopoeia. Harmonization Status for Biotechnology[EB/OL].[2019-08-13]. https://www.usp.org/harmonized-standards/pdg/biotechnology.
[10] The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q4B:Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions[EB/OL].[2007-11-01]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q4B/Step4/Q4B_Guideline.pdf.
[11] 国家药典委员会. 堆密度和振实密度测定法[EB/OL]. (2019-5-24)[2007-11-01]. http://www.chp.org.cn/upload/userfiles/20190524/1581558686743821.pdf.
[12] 国家药典委员会. 《中国药典》2020年版四部通则(草案)[M]. 第一版. 北京:中国医药科技出版社,2019:297,131,136.
[13] 施海枢. 论技术法规和产品标准的国际协调问题[D]. 北京:中国政法大学,2006.
[14] 徐昕怡,刘贞,张震,等. 中国药典片剂脆碎度检查法增修订回顾及与ICH协调的展望[J]. 中国药师,2019, 22(6):1138-1140.
[15] European Medicines Agency Inspections. European Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation Concerning Investigational Medicinal Products in Clinical Trials[EB/OL].[2019-08-13]. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/18540104en_en.pdf.
[16] US Food and Drug Administration. US Food and Drug Administration's Manual of Policies and Procedures on Acceptability of Standards from Alternative Compendia[EB/OL].[2019-08-13]. https://www.fda.gov/media/72412/download.
[17] 英国药典委员会专家来中药所学习中药DNA条形码鉴定技术[EB/OL].[2019-08-13]. http://www.catcm.ac.cn/zykxyydd/zhxw/201506/08d4ea32aa014315836191277a94ad77.shtml.
[18] British Pharmacopoeia. Supplementary Chapters VII D DNA Barcoding as a Tool for Identification of Herbal Drugs[S]. 2017.
